Global genitourinary drugs market is anticipated to witness remarkable growth over the coming seven years due to increasing prevalence of urinary disorders and related illness. In addition, technological upgradations in genitourinary devices and growing concerns pertaining to impotency & urinary incontinence are some factors expected to propel the growth of genitourinary drugs market in near future.
Full research report on Global Genitourinary Drugs Surgery Market Analysis:
The global genitourinary drugs market is divided on the basis of product and disease. By products, the market is segmented into sex hormones, gynaecologicals, urologicals and genitourinary anti infectives. The genitourinary anti invectives’ market is anticipated to register fastest growth over the forecast period due to rising prevalence of urinary tract diseases. By disease, the market is divided into renal cancer, ovarian cancer, cervical cancer, prostate cancer, bladder cancer and genitourinary cancer.
Regionally, as of 2014, North America witnessed highest market growth owing to technological advancements, favourable government policies and increasing incidences of urinary cancer. Improving healthcare awareness and increasing geriatric population base is expected to result in rapid market growth in European region. Asia pacific region is expected to witness fastest market growth over the coming seven years owing to increasing usage of effective medications, rise in personal disposable income and increasing incidence rate of urinary cancer and related disorders. Similarly, Latin American region is anticipated to register speedy growth over the forecast period due to revamped healthcare infrastructure and availability of exhaustive & cost effective drugs in this region.
Get more information on Global Genitourinary Drugs Market or request for TOC of this research report at:
The prominent players operating in global genitourinary drugs market are Merck Serono S.A., Teva Pharmaceuticals Inc., Allergan Inc., Abbott Laboratories, Hoffman La Roche, GlaxoSmithKline, Watson Pharmaceuticals Inc., Agile Therapeutics Inc., Bristol Myers Squibb, Kissei Pharmaceuticals Co. Ltd., Novo Nordisk A/S, PregLem S.A., VIVUS Inc., Isis Pharmaceuticals and Recordati S.p.A. The companies are entering into mergers, R&D activities and product modification processes to increase their market share. For example, in 2013, Allergan Inc. received FDA approval for a drug namely BOTOX. The drug is mainly used for the treatment of overactive bladder resulting in leakage, sudden urge to go and going too often. Also in 2012, Detrol LA introduced anticholinergic drug that block nerves controlling bladder muscles and allows for relaxation of muscles. These drugs also helps control the urge of urinary incontinence.
View more reports of this category by Grand View Research at:
About Grand View Research
Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.
Company Name: Grand View Research, Inc.
Contact Person: Sherry James, Corporate Sales Specialist – U.S.A.
Phone: 1-415-349-0058, Toll Free: 1-888-202-9519
Address:28 2nd Street, Suite 3036
City: San Francisco
Country: United States